Biomarkers in Schizophrenia

Summary

N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in neurocognitive dysfunction associated with schizophrenia. Further, several novel glutamate-based classes of compound are presently in development as potential novel treatments for persistent negative and cognitive symptoms. The study will assess effectiveness of a NMDA-based intervention on biomarkers related to schizophrenia as a mechanism for developing appropriate outcome batteries for future trials of novel compounds.

Timeline

Start

2009-06

Primary completion

2011-07

Completion

2011-07

Outcome

Met primary endpoint

registry analysis (superiority or other test); D-serine vs Placebo; p = 0.02; Cohen's d 0.80; Mixed Models Analysis NCT00817336 ↗

paper RESULTS: Double-blind d-serine treatment led to significant improvement in MMN frequency (p=0.001, d=2.3) generation and clinical symptoms (p=0.023, d=0.80). PMID 28318835 ↗

Publications

• Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophr Res. 2018 Jan;191:70-79. doi: 10.1016/j.schres.2017.02.027. Epub 2017 Mar 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	D-serine	Unknown	60 mg/kg	—

Indications